As the complexity of advanced therapies continues to grow, more data is needed to establish a drug’s mode of action, efficacy, and long-term safety. It’s no wonder, then, that big data is fueling the drive for tomorrow’s therapies. However, most developers lack the in-house capabilities to produce it and/or the expertise to evaluate it.
Charles River has created a complete solution for clients whose programs depend on harnessing big data. Through a new partnership with Fios Genomics, a leader in bioinformatics and analysis, clients now have expert analytical support for the microarrays, next generation sequencing (NGS), proteomics, metabolomics, epigenetics, and associated metadata that keeps their projects moving forward.
“The explosion in -omics data has been a boon for the drug discovery industry, but analysis and interpretation of these datasets are challenging,” said Birgit Girshick, Charles River’s CVP for Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services. “Through our partnership with Fios Genomics, our clients will have greater access to the special combination of skills in bioinformatics, statistics, and biology required to obtain meaningful information from their data.”